ESPE2016

10 September 2016
07:00-20:30		Registration opens
07:45-08:15		Light breakfast served for Working Group Attendees Exhibition area
08:15-10:45		ESPE Disorders of Sex Development Working Group (DSD) Chair(s):Charmian Quigley (Indianapolis, USA) & Christa Flück (Bern, Switzerland) Hormones, brain and identity: Issues in DSD The dSd Working Group welcomes the new Gender dysphoria Working Amphithéâtre Bordeaux L3
08:15	WG1.1	Biological determinants of gender identity Stephen Rosenthal (University of California San Francisco (UCSF), San Francisco, USA)
08:45	WG1.2	The brain as a target for sex steroids: recent trends in endocrine neuroimaging Sven Müller (Ghent, Belgium)
09:15	WG1.3	Gender dysphoria and DSD Peggy Cohen-Kettenis (Amsterdam, The Netherlands)
09:45	WG1.4	Health care situation of persons with DSD: first results from DSD-LIFE Birgit Köhler (Berlin, Germany)
10:00	WG1.5	DSD nomenclature, a report of the patients' views in the DSD-LIFE study Ute Thyen (Lübeck, Germany)
10:15	WG1.6	Fertility and fecundity, reports from the DSD-LIFE study Anna Nordenström (Karolinska University Hospital, Stockholm, Sweden)
10:30		DSD WG Buisness meeting
08:15-10:45		ESPE Obesity Working Group (OWG) Chair(s):Jesús Argente (Madrid, Spain) & Julie Chowen (Madrid, Spain) Clinical and neuroendocrinological advances in obesity 252 AB L2
08:15	WG2.1	Welcome and introduction Jesús Argente (Madrid, Spain)
08:20	WG2.2	Bariatric surgery in obese adolescents Jovanna Dahlgren (Sweden)
08:50	WG2.3	Clinical approach to severe early onset childhood obesity Gabriel Martos-Moreno (Madrid, Spain)
09:20	WG2.4	Tanycyte transport of leptin into the hypothalamus: implications in leptin resistance Vincent Prevot (University of Lille, Lille, France)
09:50	WG2.5	Palatability can drive feeding independent of AgRP neurons Serge Luguet (Paris, France)
10:20		Obesity WG Business meeting
08:15-10:45		ESPE Turner Syndrome Working Group (TS) Chair(s):08:15 - 09:15: Malgorzata Wasniewska (Messina, Italy) & Aneta Gawlik (Katowice, Poland), 09:30 - 10:30: Laura Mazzanti (Bologna, Italy) & Malcolm Donaldson (Glasgow, UK) Understanding TS beyond height Salle Maillot L2
08:15	WG3.1	Spontaneous fertility and pregnancy outcomes in TS Sophie Christin-Maitre (Paris, France)
08:45	WG3.2	Skeletal disproportion in Turner Syndrome Jarod Wong (Glasgow, UK)
09:30	WG3.3	Patient coaching and education in TS: a Dutch approach Helen Mijnarends (Maastricht, The Netherlands)
10:00	WG3.4	Face perception in TS Vardit Gepstein (Haifa, Israel)
10:30	WG3.5	Estradiol supplementation in TS : an update Theo Sas (Rotterdam, The Netherlands)
08:15-10:45		ESPE Bone and Growth Plate Working Group (BGP) Chair(s):08:15 - 09:15: Ola Nilsson (Gothenburg, Sweden) & Ciara McDonnell (Dublin, Ireland) 09:15 - 10:45 Serup Turan (Istanbul, Turkley) & Eckhard Schönau (Cologne, Germany) Disorders of growth, bone and mineral disorders – novel insights and future directions Amphithéâtre Bleu L2
08:15	WG4.1	Genetics of overgrowth syndromes Kate Tatton-Brown (London, UK)
08:45	WG4.2	Hypercalcaemic disorders in children Raj Thakker (Oxford, United Kingdom)
09:15	WG4.3	Bisphosphonate treatment in rare bone diseases Nick Bishop (Sheffield, UK)
09:45	WG4.4	A clinical and genetic approach to diagnosis and treatment of fractures in infancy Oliver Semler (Cologne, Germany)
10:15	WG4.5	FGF23, Klotho and PTH in the regulation of mineral homeostasis Thomas Carpenter (New Haven, USA)
08:15-10:45		ESPE Diabetes Technology and Therapeutics Working Group Chair(s):Moshe Phillip (Petah Tikva, Israel) & Thomas Danne (Hannover, Germany) Challenges in Diabetes Grand Amphithéâtre L2
08:15	WG5.1	Introduction Moshe Phillip (Israel)
08:20	WG5.2	Center of Excellence/Sweet project Thomas Danne (Hannover, Germany)
08:45	WG5.3	Use and discontinuation of CSII and CGM treatment in the paediatric age group – rates and causes Shlomit Shalitin (Petah Tikva, Israel)
09:10	WG5.4	Debate - PRO: Use of Dual Hormone (glucagon) v. single hormone (insulin) in the treatment of diabetes with close-loop system Revital Nimri (Petah Tikva, Israel)
09:10	WG5.5	Debate - CON: Use of Dual Hormone (glucagon) v. single hormone (insulin) in the treatment of diabetes with close-loop system Tadej Battelino (University of Ljublijana, Ljubljana, Slovenia)
09:50	WG5.6	Prescribing software for the treatment of diabetes Moshe Phillip (Israel)
10:15	WG5.7	Interaction between humans and technology in the treatment of diabetes Katharine Barnard (Southampton, UK)
08:15-10:45		ESPE Paediatric and Adolescent Gynaecology Working Group (PAG) Chair(s):Part 1: Feyza Darendeliler (Istanbul, Turkey) & Anders Juul (Copenhagen, Denmark) Part 2: Anne-Sophie Parent (Liège, Belgium) & Michel Polak (Paris, France) Functional hypothalamic amenorrhea and breast disorders 342 AB L3
08:15	WG6.1	Stress and amenorrhea Flora Bacopoulou (Athens, Greece)
08:45	WG6.2	Anorexia & amenorrhea Madhusmita Misra (Boston, USA)
09:15	WG6.3	Physical exercise and amenorrhea Neoklis Georgopoulos (Patras, Greece)
09:45	WG6.4	Breast cancer risk in adolescent girls Christine Rousset-Jablonski (Lyon, France)
10:15	WG6.5	Benign breast conditions in adolescent girls Philippe Touraine (Pitié Salpêtrière Hospital, Paris, France)
11:00-11:15		Opening Ceremony Welcome and opening speeches: Jean-Claude Carel, Agnès Linglart & Peter Clayton Grand Amphithéâtre L2
11:15-11:45		Plenary 1 Chair(s):Michel Polak (Paris, France) & Stefano Cianfarani (Rome, Italy) Grand Amphithéâtre L2
11:15	PL1	Environmental chemicals, brain development and human intelligence Barbara Demeneix (Paris, France)
11:45-12:15		ESPE awards Chair(s):Anita Hokken-Koelega (Rotterdam, The Netherlands) ESPE Young Investigator Award 1 & 2, ESPE Research Award, IFCAH-ESPE award Grand Amphithéâtre L2
12:15-12:45		Plenary 2 Chair(s):George P Chrousos (Athens, Greece) & Constantine Stratakis (Bethesda, USA) Grand Amphithéâtre L2
12:15	PL2	Recent advances on the genetics of adrenal hyperfunction and tumors Jerome Bertherat (Paris Descartes University, France)
12:45-14:30		Lunch, posters and exhibition Exhibition area
13:15-14:15		Industry Sponsored Satellite Symposia Grand Amphithéâtre L2
14:30-16:00		Symposium 1: Innovative therapies in bone and mineral metabolism Chair(s):Agnès Linglart (Paris, France) & Wolfgang Högler (Birmingham, UK) Grand Amphithéâtre L2
14:30	S1.1	Anti FGF23 in X-linked hypophosphatemia Thomas Carpenter (New Haven, USA)
15:00	S1.2	Denosumab as an alternative to bisphosphonates in osteogenesis Eckhard Schönau (Cologne, Germany)
15:30	S1.3	Modulating FgFr3 signalling to treat achondroplasia Laurance Legeai-Mallet (Paris, France)
14:30-16:00		Symposium 2: Genetics and epigenetics of thyroid dysgenesis Chair(s):Heiko Krude (Berlin, Germany) & Juliane Léger (Paris, France) Amphithéâtre Bordeaux L3
14:30	S2.1	Early thyroid development Heiko Krude (Berlin, Germany)
15:00	S2.2	Random monoallelic expression in thyroid tissue: implications for development, immune disorders and neoplasia Johnny Deladoey (Montreal, Canada)
15:30	S2.3	Genetics of thyroid dysgenesis and associated malformations Michel Polak (Paris, France)
14:30-16:00		Symposium 3: Optimizing nocturnal diabetes control - Joint ISPAD-ESPE Session Chair(s):Zdeněk Šumník (Prague, Czech Republic) & Ragnar H˚anas (Uddevalla, Sweden) Amphithéâtre Bleu L2
14:30	S3.1	Sleep and glycaemic control in children with type 1 diabetes Karine Spiegel (Lyon, France)
15:00	S3.2	Therapeutic implications Thomas Danne (Hannover, Germany)
15:30	S3.3	New insulins, new technology: but where is the evidence? Roman Hovorka (Cambridge, UK)
14:30-16:00		Symposium 4: New avenues in paediatric autoimmune disease Chair(s):Reiko Horikawo (Tokyo, Japan) & Cheri Deal (Montréal, Canada) 342 AB L3
14:30	S4.1	Activating mutations in STAT3 leading to early-onset multi-organ autoimmune disease Megan Cooper (St. Louis, USA)
15:00	S4.2	The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases David Klatzmann (Paris, France)
15:30	S4.3	Beta cells in type 1 diabetes: insights from the nPOD study Alberto Pugliese (Miami, USA)
14:30-16:00		Special Session 1: Online learning in education and training: Future prospects and ESPE e-Learning activities Chair(s):Annemieke Boot (Groningen, The Netherlands) & Amit Pandey (Bern, Switzerland) Salle Maillot L2
14:30	SS1.1	Introduction
14:35	SS1.2	Application of online learning in assessment of competencies of fellows in paediatric endocrinology
14:50	SS1.3	The use of educational technology and open online courses in medical teaching Peter Jong (Leiden, The Netherlands)
15:15	SS1.4	Continuing Medical Education (CME) and Continuing Professional Development (CPD) in the past and future Vassilios Papalois (Brussels, Belgium)
15:40	SS1.5	Objectives and outcome of ESPE Schools Malcolm Donaldson (Glasgow, United Kingdom)
15:55	SS1.6	Discussions and Q & A on ESPE E-learning activities
16:00-16:15		Refreshment break, posters and exhibition Exhibition area
16:15-17:15		Yearbook of Paediatric Endocrinology - YB1 Chair(s):Francesco Chiarelli (Chieti, Italy) Grand Amphithéâtre L2
	YB1.1	Adrenals Evangelia Charmandari (Athens, Greece)
	YB1.2	Evidence based medicine in paediatric endocrinology Chris Kelnar (Edinburgh, UK)
	YB1.3	Global health for the paediatric endocrinologist Jean-Pierre Chanoine (Vancouver, Canada)
	YB1.4	Type 2 diabetes, metabolic syndrome and lipids Orit Pinhas-Hamiel (Tel Aviv, Israel)
	YB1.5	The year in science & medicine Ze'ev Hochberg (Haifa, Isreal))
16:15-17:15		Meet the Expert 1 252 AB L2
16:15	MTE1.1	Clinical management of transgender youth Olle Söder (Stockholm, Sweden)
16:15-17:15		Meet the Expert 2 342 AB L3
16:15	MTE2.1	Hypertension in children Jörg Dötsch (Köln, Germany)
16:15-17:15		Meet the Expert 3 Salle Maillot L2
16:15	MTE3.1	Glucocorticoid induced fractures Outi Mäkitie (Helsinki, Finland)
16:15-17:15		Meet the Expert 4 Amphithéâtre Bordeaux L3
16:15	MTE4.1	Neonatal Graves' disease Juliane Léger (Paris, France)
17:30-19:00		Industry Sponsored Satellite Symposia Grand Amphithéâtre L2, Amphithéâtre Bleu L2, Salle Maillot L2
17:45-19:15		Gender Dysphoria meeting 224 &225M
19:00-20:30		Informal ESPE Networking Event Exhibition area
11 September 2016
07:00-19:30		Registration opens
08:00-09:00		Meet the Expert 5 342 AB L2
08:00	MTE5.1	Hypercholesterolaemia in children Albert Wiegman (Amsterdam, The Netherlands)
08:00-09:00		Meet the Expert 6 Salle Maillot L2
08:00	MTE6.1	Prolactinomas in adolescence Philippe Chanson (Paris, France)
08:00-09:00		Meet the Expert 7 Amphithéâtre Bordeaux L3
08:00	MTE7.1	Neonatal hypocalcaemia Serap Turan (Istanbul, Turkey)
08:00-09:00		Meet the Expert 8 252 AB L2
08:00	MTE8.1	Steroid measurements in paediatric endcrinology Yves Morel (Lyon, France)
08:00-09:00		Meet the Expert 2 (repeated) Amphithéâtre Bleu L2
08:00	MTE2.2	Hypertension in children Jörg Dötsch (Köln, Germany)
09:15-10:15		Yearbook of Paediatric Endocrinology - YB2 Chair(s):Anders Juul (Copenhagen, Denmark) Grand Amphithéâtre L2
	YB2.1	Thyroid Gabor Szinnai (Basel, Switzerland)
	YB2.2	Oncology and chronic Disease Carla Bizzarri (Rome, Italy)
	YB2.3	Reproductive endocrinology Olle Söder (Stockholm, Sweden)
	YB2.4	Bone, growth plate and mineral metabolism Outi Mäkitie (Helsinki, Finland)
	YB2.5	Editor's Choice Ken Ong (Cambridge, UK)
09:15-10:45		RFC & FC 1 - Adrenals Chair(s):Lou Metherel (London, UK) & Ze'ev Hochberg (Haifa, Israel) Amphithéâtre Bleu L2
	RFC1.1	Tracing the Glucocorticoid Receptor evolutionary pedigree: insights from a comprehensive phylogenetic analysis of the full NR super-family Dimitrios Vlachakis (Athens, Greece)
	RFC1.2	Glucocorticoid deficiency due to disruption of mitochondrial steroidogenesis leads to dysregulation of antioxidant pathways and nucleotide biosynthesis Meltem Weger (Birmingham, UK)
	RFC1.3	Impaired cardiac function in a mouse model of Generalized Glucocorticoid Resistance Evangelia Charmandari (Athens, Greece)
	RFC1.4	Mutations of ABCD1 in 16 Vietnamese Patients with X-linked Adrenoleukodystrophy Dung Vu (Hanoi, Vietnam)
	RFC1.5	A novel animal model to study 21-hydroxylase deficiency in vivo Andreas Zaucker (Birmingham, UK)
	RFC1.6	Paediatric patients with congenital adrenal hyperplasia have unfavorable changes in their cardiovascular risk profile Christiaan Mooij (Nijmegen, The Netherlands)
	RFC1.7	The recovery of adrenal function in children with chronic asthma assessed by Low Dose Short Synacthen Test (LDSST) Arundoss Gangadharan (Liverpool, UK)
	RFC1.8	Adrenal dysfunction in HIV-exposed uninfected infants receiving ritonavir-boosted lopinavir, an HIV protease inhibitor, for the prevention of breastfeeding HIV transmission. An ANRS 12174 substudy. Michel Polak (Paris, France)
09:45	FC1.1	DNA methylation of HSD3B2, NUR77 and RARβ promoter genes is not involved in functional differentiation of human androgen-producing adrenocortical cells Maria Burgos (Ciudad, Argentina)
09:55	FC1.2	Transcriptomic Analysis in Healthy Subjects with Differences in Tissue Sensitivity to Glucocorticoids Identifies Novel Disease-associated Genes Nicolas Nicolaides (Athens, Greece)
10:05	FC1.3	Steroidogenesis in the human fetal adrenals at the end of the first trimester Iuliia Savchuk (Stockholm)
10:15	FC1.4	Identification of novel central nervous system imaging biomarkers associated with cognitive abnormalities in patients with congenital adrenal hyperplasia Emma Webb (Jenny Lind Children’s Hospital, Norwich, UK)
10:25	FC1.5	AAV gene therapy of 21-hydroxylase deficiency (21OHD) in Cyp21-/- mice Pierre Bougneres (French Institute of Health and Medical Research, Bicêtre, France)
10:35	FC1.6	A novel syndrome of IUGR, congenital adrenal and gonadal insufficiency, severe infections, thrombocytopenia and monosomy 7 is caused by SAMD9 mutations Federica Buonocore (London, UK)
09:15-10:45		RFC & FC 2 - Bone & Mineral Metabolism Chair(s):Oliver Semler (Cologne, Germany) & Ola Nilsson (Stockholm, Sweden) Amphithéâtre Bordeaux L3
	RFC2.1	25-OH-Vitamin D status in a paediatric population of subjects affected by Prader-Willi Syndrome compared to matched obese controls Danilo Fintini (Rome, Italy)
	RFC2.2	Duration of exclusive breastfeeding: ‘Game changer’ in a sex-specific association between cord vitamin D status and infant linear growth. Anna Christensen (Odense, Denmark)
	RFC2.3	Cord vitamin D is inversely associated with systolic and diastolic blood pressure in 3-year-old girls, but not in boys. Søs Larsen (Odense C, Denmark)
	RFC2.4	Results of orthopaedic surgery in children with X-linked hypophosphatemic rickets (XLHR) Dr. Anya Rothenbuhler (Paris, France)
	RFC2.5	Growth Patterns And Fractures In Boys With Duchenne Muscular Dystrophy: Insights From Over 800 Boys In The UK North Star Cohort Sze Choong Wong (University of Glasgow, Glasgow, UK)
	RFC2.6	Combining COLD and MAMA-PCR real time taqman tecniques to detect and quantify the R201 GNAS mutation causing McCune-Albright Syndrome Luisa Sanctis (Torino, Italy)
	RFC2.7	Effect of paternal loss-of-function mutations of GNAS on growth during the childhood: a role for XL. Lea Tran (Caen, France)
	RFC2.8	Final heights and BMI in patients affected with different types of pseudohypoparathyroidism Patrick Hanna (Paris, France)
09:45	FC2.1	Characterization of GNAS miRNAs targets: trying to better understand the pathophysiology of pseudohypoparathyroidism 1B (PHP1B) Patrick Hanna (Paris, France)
09:55	FC2.2	From Pseudohypoparathyroidism to inactivating PTH/PTHrP Signaling Disorder (iPPSD), a novel classification proposed by the European EuroPHP-network Susanne Thiele-Schmitz (Lübeck, Germany)
10:05	FC2.3	The impact of intragastric balloon placement suppported by a lifestyle intervention programme on cortical and trabecular microstructure and strength in severely obese adolescents Pooja Sachdev (Nottingham University Hospitals NHS Trust, Nottingham , UK)
10:15	FC2.4	In vitro evidence that growth plate chondrocytes differentiate into perichondrial cells. Anenisia Andrade (Stockholm, Sweden)
10:25	FC2.5	Determination of the Minimal Clinically Important Difference in the Six-Minute Walk Test for Patients with Hypophosphatasia Ioannis Tomazos (New Haven, USA)
10:35	FC2.6	Effect of KRN23, a Fully Human Anti-FGF23 Monoclonal Antibody, on Rickets in Children with X-linked Hypophosphatemia (XLH): 40-week Interim Results from a Randomized, Open-label Phase 2 Study Agnès Linglart, MD, PhD (Paris, France)
09:15-10:45		RFC & FC 3 - Pituitary Chair(s):Roland Pfäffle (Leipzig, Germany) & Rachel Reynaud (Marseille, France) Salle Maillot L2
	RFC3.1	Endocrinopathy in Childhood Intracranial Germ Cell Tumours is Predicted by Disease Location not Treatment: 30 Year Experience From a Single Tertiary Centre Joana Serra-Caetano (London, UK)
	RFC3.2	Subfertility After Chemotherapy in PNET tumours: 34 Year Experience From a Single Centre (1980-2013) Joana Serra-Caetano (London, UK)
	RFC3.3	Unraveling the Link Between Optic Nerve Hypoplasia and Pituitary Hormone Dysfunction Naseem Alyahyawi (Vancouver, Canada)
	RFC3.4	Children and adolescents with severe TBI can develop late pituitary dysfunction independently of the results of the first pituitary evaluation. Yamina Dassa (Paris, France)
	RFC3.5	Prospective dynamic evaluation of hypothalamo-pituitary function in 30 cases of paediatric craniopharyngioma, by hypothalamic injury and treatment; a single centre series. Chiara Guzzetti (London, UK)
	RFC3.6	Priority target conditions of growth-monitoring in children: toward consensus Pauline Scherdel (Paris, France)
	RFC3.7	Pituitary structural abnormalities in idiopathic isolated growth hormone deficiency Luís Cardoso (Coimbra, Portugal)
	RFC3.8	Anthropometric and endocrine features in children and adolescents with Type 1 Narcolepsy. Antonio Balsamo (Bologna, Italy)
09:45	FC3.1	The MAPK effector BRAF is essential for the integrity of hypothalamic-pituitary development and deregulation of this pathway causes congenital hypopituitarism. Carles Gaston-Massuet (University of London , London, UK)
09:55	FC3.2	Spectrum of LHX4 mutations in a cohort of 510 patients with hypopituitarism Enzo Cohen (Paris, France)
10:05	FC3.3	Contribution of GLI2 mutations to pituitary deficits and delineation of the associated phenotypic spectrum Enzo Cohen (Paris, France)
10:15	FC3.4	A novel mutation in eukaryotic translation initiation factor 2 subunit 3 (EIF2S3) is associated with X-linked hypopituitarism and glucose dysregulation. Louise. Gregory (London, UK)
10:25	FC3.5	Septo-optic dysplasia spectrum: pubertal features of a large cohort of children and adolescents with septo-optic dysplasia, congenital hypopituitarism and optic nerve hypoplasia from a single centre Manuela Cerbone (London, UK)
10:35	FC3.6	Pegvisomant is more effective in stunting growth than somatostatin analogs in childhood acromegaly/gigantism. Cecile Thomas-Teinturier (Bicetre, France)
09:15-10:45		RFC & FC 4 - Pathophysiology of Obesity Chair(s):Wieland Kiess (Leipzig, Germany) & Julie Chowen (Madrid, Spain) 252 AB L2
	RFC4.2	Adipocytokines delay pubertal maturation of human Sertoli cells Isabel Wagner (Stockholm, Sweden)
	RFC4.3	Early growth patterns are associated with alterations in adipocytokine levels and fat distribution measured by DXA in 982 children/adolescents. Jeanette Tinggaard (Copenhagen, Denmark)
	RFC4.4	Metabolic syndrome markers correlate with gut microbiome activity in children born very preterm Valentina Chiavaroli (Auckland, New Zealand)
	RFC4.5	Steroid Metabolomic Signature of Liver Disease in Childhood Obesity Aneta Gawlik (Katowice, Poland)
	RFC4.6	Adipose tissue - a source of hyperandrogenism in obese females? Isabel Wagner (Stockholm, Sweden)
	RFC4.7	Prevalence and characterization of retinal alterations in a cohort of overweight and obese children Stefania Pedicelli (Rome, Italy)
09:45	FC4.1	Contribution of rare CNVs and point mutations to the etiology of severe early-onset obesity Clara Serra-Juhé (Barcelona)
09:55	FC4.2	Immune-fat-bone axis in obese children: the role of LIGHT Giacomina Brunetti (Bari, Italy)
10:05	FC4.3	Expression of type 1 insulin-like growth factor receptor (IGF-1R) in liver of obese children with non-alcoholic fatty liver disease (NAFLD) Valentina Pampanini (Rome, Italy)
10:15	FC4.4	The role of apoptotic marker Apo-1/Fas in the metabolism and endothelial function of healthy children Maria Maganna (Sparta, Greece)
10:25	FC4.5	Novel association between the non-synonymous A803G polymorphism of the N-acetyltransferase 2 gene and impaired glucose homeostasis in obese children and adolescents. Pierluigi Marzuillo (Naples, Italy)
10:35	FC4.6	The rise and fall of the Swedish childhood obesity epidemic – The BEST cohort Maria Bygdell (Gothenburg, Sweden)
09:15-10:45		RFC & FC 5 - Management of Disorders of Insulin Secretion Chair(s):Carlo Acerini (Cambridge, UK) & Nadia Tubiana-Rufi (Paris, France) 342 AB L3
	RFC5.1	Adiponectin and leptin in children with type 1 diabetes for 3-5 years with or without residual β cell function. Niels Birkebaek (Aarhus, Denmark)
	RFC5.2	Limits of agreement between HbA1c levels measured in different laboratories following the introduction of the International Federation of Clinical Chemistry and Laboratory Medicine standardised values Joanne Blair (Liverpool, UK)
	RFC5.3	Sexual lifestyle among young adults with type 1 diabetes Orit Pinhas-Hamiel (Tel-Aviv, Israel)
	RFC5.4	"Transient" neonatal diabetes in adulthood: Metabolic outcomes Kanetee Busiah (Paris, France)
	RFC5.5	The efficacy of insulin degludec in children and adolescents with type 1 diabetes. Lorenzo Iughetti (Modena, Italy)
	RFC5.6	Clinical management of the Mitchell-Riley syndrome due to RFX6 gene mutations: aggressive support results in improved outcome Amélie Poidvin (Paris, France)
	RFC5.7	Early successful hematopoietic cell transplantation (HSCT) in a boy with IPEX syndrome caused by novel c.721T>C FOXP3 mutation Barbora Obermannova (Prague, Czech Republic)
09:45	FC5.1	The anti-diabetic drug, metformin, suppresses adipogenesis through both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms Suet Ching Chen, MD (Glasgow, UK)
09:55	FC5.2	Diabetes and insulin injection modalities: Effects on hepatic expression and activity of 11β-hydroxysteroid dehydrogenase type 1 in juvenile diabetic rats. Pascal Barat (Bordeaux, France)
10:05	FC5.3	Glibentek, a new suspension of glibenclamide for patients with neonatal diabetes, is as effective and more convenient than crushed tablets Jacques Beltrand (Paris, France))
10:15	FC5.4	Persistent beneficial metabolic effect after five years in a cohort of 28 subjects with neonatal diabetes owing to potassium channel mutation and transferred from insulin to sulfonylureas Jacques Beltrand (Paris, France))
10:25	FC5.5	DPP-4 inhibitor is an alternative effective treatment in a common cause of anti-GAD negative "type 1 Diabetes" - A founder CISD2 mutation Ulla Abdulhag (Jerusalem, Israel)
10:35	FC5.6	Impact of continuous subcutaneous insulin infusion versus multiple daily injections on bone health in children and adolescents with type 1 diabetes Maria Faienza (Bari, Italy)
10:45-11:15		Refreshment break, posters and exhibition Exhibition area
11:15-11:30		ESPE Awards Chair(s):Mehul Dattani (London, UK) Henning Andersen Prizes (best basic and clinical) Grand Amphithéâtre L2
11:30-12:00		Plenary 3 Chair(s):Faisal Ahmed (Glasgow, UK) & Agnès Linglart (Paris, France) Grand Amphithéâtre L2
11:30	PL3	Calcium-sensing receptor signalling in physiology and diseases Raj Thakker (Oxford, United Kingdom)
12:00-12:30		ESPE Awards Chair(s):Peter Clayton (Manchester, UK) Andrea Prader Prize Grand Amphithéâtre L2
12:30-13:00		Plenary 4 Chair(s):Anita Hokken-Koelega (Rotterdam Netherlands) & Irène Netchine (Paris, France) Grand Amphithéâtre L2
12:30	PL4	Genomic imprinting and evolution Robert Feil (Montpellier, France)
13:00-14:30		Lunch, posters and exhibition Exhibition area
13:15-14:15		Industry Sponsored Satellite Symposia Salle Maillot L2
14:15-16:30		ESPE Paediatric Endocrine Nurse Specialists and Allied Health Professionals Working Group (PENS) Chair(s):Jan Foote (De Moines, USA) & Christine Derycke (Brussels, Belgium) Beyond the patient, Au-Dela du Patient 342 AB L3
14:15	WG7.1	Welcome
14:25	WG7.2	The activities of AdrenalNET and the paediatric emergency card for Europe Johan Beun ('t Harde, The Netherlands)
15:15	WG7.3	Empowering nurses as scholars Terri Lipman (Philadelphia, USA)
16:00	WG7.4	Poster review
16:15	WG7.5	Questions and discussion
14:30-15:30		Novel Advances in Paediatric Endocrinology: Non-invasive prenatal diagnosis Chair(s):Outi Mäkitie (Helsinki, Finland) & Jesús Argente (Madrid, Spain) 252 AB L2
14:30	NA1.1	Non invasive prenatal diagnosis in paediatric endocrinology Lyn Chitty (London, UK)
15:00	NA1.2	Intrauterine imaging strategies for bone disease Yasemin Alanay (Istanbul, Turkey)
14:30-16:00		Symposium 5: Mitochondrial dysfunction and endoplasmic reticulum stress in endocrine diseases Chair(s):David Dunger (Cambridge, UK) & Yves Morel (Lyon, France) Salle Maillot L2
14:30	S5.1	Endoplasmic reticulum stress and diabetes Fumihiko Urano (St Louis, USA)
15:15	S5.3	Activation of HSP 72: a therapeutic target for diseases related to both ER stress and mitochondrial dysfunction Mark Febbraio (Monash University, Melbourne, Australia)
14:30-16:00		Symposium 6: Prevention of childhood obesity Chair(s):Jan Lebl (Prague, Czech Republic) & Gary Butler (UK) Grand Amphithéâtre L2
14:30	S6.1	Long term consequences of childhood obesity Paul Franks (Lund, Sweden)
15:00	S6.2	Early childhood life style intervention and obesity outcome Claude Marcus (Solna, Sweden)
15:30	S6.3	What do we need and how are we doing? A European perspective Johannes Brug (Amsterdam, The Netherlands)
14:30-16:00		Symposium 7: Overgrowth disorders Chair(s):Mohammad Maghnie (Genoa, Italy) & Yves Le Bouc (Paris, France) Amphithéâtre Bleu L2
14:30	S7.1	Clinical management of overgrowth disorders Trevor Cole (Birmingham, UK)
15:00	S7.2	NGS in identifiying the molecular basis of overgrowth syndromes Robert Semple (University of Edinburgh, Edinburgh, UK)
15:30	S7.3	The role of GPR101 in human growth Constantine Stratakis (Greece)
14:30-16:00		Controversies - Challenges in the Management of DSD Chair(s):Nils Krone (Sheffield, UK) & Laura Audí (Barcelona, Spain) Amphithéâtre Bordeaux L3
14:35	CON1.1	Case presentation of a difficult case Martine Cools (Ghent, Belgium)
14:45	CON1.2	Surgical management of DSD - new insights
15:15	CON1.3	Psychological challenges Franco D'Alberton (Bologna, Italy)
15:25	CON1.4	An ethicist's viewpoint Claudia Wiesemann (Göttingen, Germany)
15:35		Panel Discussion
16:00-16:30		Refreshment break, posters and exhibition Exhibition area
16:30-18:00		Industry Sponsored Satellite Symposia Grand Amphithéâtre L2, Amphithéâtre Bleu L2, Salle Maillot L2
18:15-19:30		ESPE Annual Business Meeting Salle Maillot
12 September 2016
07:00-17:45		Registration opens
08:00-09:00		Yearbook of Paediatric Endocrinology - YB3 Chair(s):Wieland Kiess (Leipzig, Germany) Grand Amphithéâtre L2
	YB3.1	Pituitary and neuroendocrinology Nicolas de Roux (Paris, France)
	YB3.2	Growth and growth factors Stefano Cianfarani (University of Rome Tor Vergata, Rome, Italy)
	YB3.3	Antenatal and neonatal endocrinology Khalid Hussain (Sidra Medicine, Doha, Qatar)
	YB3.4	Obesity and weight regulation Professor Martin Wabitsch (University of Ulm, Germany)
	YB3.5	Type 1 diabetes Wieland Kiess (Hospital for Children and Adolescence, University of Leipzig, Leipzig, Germany)
08:00-09:00		Meet the Expert 1 (repeated) Amphithéâtre Bordeaux L3
08:00	MTE1.2	Clinical management of transgender youth Olle Söder (Stockholm, Sweden)
08:00-09:00		Meet the Expert 3 (repeated) Salle Maillot L2
08:00	MTE3.2	Glucocorticoid induced fractures Outi Mäkitie (Helsinki, Finland)
08:00-09:00		Meet the Expert 4 (repeated) Amphithéâtre Bleu L2
08:00	MTE4.2	Neonatal Graves' disease Juliane Léger (Paris, France)
08:00-09:00		Meet the Expert 5 (repeated) 252AB L2
08:00	MTE5.2	Hypercholesterolemia in children Albert Wiegman (Amsterdam, The Netherlands)
08:00-10:00		Special Session 2: GPED activities Chair(s):Asma Deeb (Abu Dhabi, UAE) & Ze'ev Hochberg (Haifa, Israel) Improving health through growth monitoring in low-middle income countries 342 AB
08:00	SS2.1	Growth monitoring for improved health Kerstin Albertsson-Wikland (Gothenburg, Sweden)
08:20	SS2.2	Nationwide implementation of the WHO growth charts in Canada Jean-Pierre Chanoine (Vancouver, Canada)
08:40	SS2.3	Tomorrow: automated growth monitoring goes worldwide Leo Dunkel (London, UK)
09:05	SS2.4	Kenyan experience of online monitoring and referral network Thomas Ngwiri (Nairobi, Kenya)
09:15	SS2.5	The challenge of implementing growth measurements and growth charts in resource limited settings Joel Dipesalema (Gaborone, Botswana)
09:30	SS2.6	Growth monitoring in India: current status and challenges Ganesh Jevalikar (Mumbai, India)
09:45	SS2.7	General discussion
09:15-10:15		Novel Advances in Paediatric Endocrinology 2: Non-coding RNA in paediatric endocrinology Chair(s):Nicolas de Roux (Paris, France) & Luis Castano (Bilbao, Spain) Grand Amphithéâtre L2
09:15	NA2.1	Decoding obesity - control of metabolism by the noncoding transcriptome Jan-Wilhelm Kornfeld (Cologne, Germany)
09:45	NA2.2	Imprinted small non-coding RNA genes and neonatal metabolic adaptation Jérome Cavaillé (Toulouse, France)
09:15-10:45		RFC & FC 6 - Syndromes: Mechanisms and Management Chair(s):Feyza Darendelier (Istanbul, Turkey) & Rasa Verkauskiene (Kaunas, Lithuania) Amphithéâtre Bleu L2
	RFC6.2	RAB3IP and DGCR8 as a potentially pathogenic novel candidate gene involving in growth disorders Thais Homma (Sao Paulo, Brazil)
	RFC6.3	Effect of Very Early Growth Hormone (GH) Treatment on Long-term Growth in Girls with Turner Syndrome (TS): A Multicenter, Open-Label, Extension Study Hiren Patel (Indiana, USA)
	RFC6.4	Growth hormone (GH) treatment in skeletal dysplasias – Short-term results in prepubertal children reported in KIGS Lars Hagenäs (Stockholm, Sweden)
	RFC6.5	Abnormal Videofluoroscopic Swallow Studies (VFSS) in Infants with Prader-Willi Syndrome Indicate a High Rate of Silent Aspiration Parisa Salehi (Seattle, USA)
	RFC6.6	Growth Hormone (GH) Deficiency Type II: Clinical and Molecular Evidence of Impaired Regulated GH Secretion Due to an Gln181Arg GH-1 Gene Mutation Maria Consolata Miletta (New Haven, USA)
	RFC6.7	Characteristics of responders and poor-responders to Increlex® therapy – data from children enrolled in the European Increlex® Growth Forum Database (EU-IGFD) Peter Bang (Linköping, Sweden)
	RFC6.8	The actual incidence of Small for Gestational Age (SGA) newborns and their catch-up growth is dramatically lower than previously considered. Eran Lavi (Jerusalem, Israel)
09:45	FC6.1	Ghrelin-reactive autoantibodies are elevated in children with Prader-Willi Syndrome compared to unaffected sibling controls Gabrielle Crisp (Brisbane, Australia)
09:55	FC6.2	Whole exome sequencing identifies EPHB4 and PIk3R6 as causes of generalized lymphatic anomaly Dong Li (Philadelphia, USA)
10:05	FC6.3	Oxytocin improves social and food-related behavior in young children with Prader-Willi Syndrome: A randomized, double-blind, controlled crossover trial Renske Kuppens (Rotterdam, The Netherlands)
10:15	FC6.4	Chromosome 14 imprinted region DLK1/GTL2 disruption: an alternative molecular etiology for Silver-Russell Syndrome Sophie Geoffron (Paris, France)
10:25	FC6.5	Pathogenic copy number variants are frequently identified in children with short stature of unknown etiology Thais Homma (Sao Paulo, Brazil)
10:35	FC6.6	Social cognition skills and face perception in Turner syndrome (TS) Vardit Gepstein (Haifa, Israel)
09:15-10:45		RFC & FC 7 - Gonads & DSD Chair(s):Anna Nordenstrom (Stockholm, Sweden) & Berenice Mendonca (São Paolo, Brasil) Amphithéâtre Bordeaux L3
	RFC7.1	Tissue engineered collagen based tubular scaffolds for urethral regeneration. A novel technology for the surgical treatment of VSD (Variation of Sex Development) patients with severe hypospadias. Kalitha Pinnagoda (Lausanne, Switzerland)
	RFC7.2	Reference values for external genitalia size and steroid hormone levels in female neonates. Sarah Castets (Lyon, France)
	RFC7.3	Harmonisation of Serum Dihydrotestosterone Analysis: Establishment of an External Quality Assurance Program Stefan Wudy (Justus-Liebig-Universität Gießen, Giessen, Germany)
	RFC7.4	A Mutation in WT1 (Wilms' tumor suppressor 1) associated with 46,XX TDSD Caroline Eozenou (Paris, France)
	RFC7.5	Fertility preservation in an adolescent boy: Inducing puberty and spermatogenesis prior to Bone Marrow transplantation Cindy Ho (Victoria, Australia)
	RFC7.6	The hopeful beginnings of fertility preservation in children Cindy Ho (Victoria, Australia)
	RFC7.7	Clinical Decision-Making in Disorders of Sex Development (DSD): Physician Recommendations Pre- and Post-Consensus Statement David Sandberg (Michigan, USA)
	RFC7.8	Premature adrenarche in girls at pubertal onset is associated with high androgens, but lower AMH concentrations Paulina Merino (Santiago, Chile)
09:45	FC7.1	Early Loss of Germ Cells in Testis of Androgen Insensitivity Syndrome Patients Esperanza Berensztein (Buenos Aires, Argentina)
09:55	FC7.2	Serum irisin concentrations in lean adolescents with polycystic ovary syndrome Flora Bacopoulou (Athens, Greece)
10:05	FC7.3	Estrogen insensitivity due to a novel ESR1 mutation in a consanguineous family from Algeria Sakina Kherra (Laghouat, Algeria)
10:15	FC7.4	Disruption of long-range transcriptional regulation of genes known to be associated with DSD Selma Witchel (Pittsburgh, USA)
10:25	FC7.5	Targeted Exome Sequencing for Genetic Diagnosis of Patients with Disorders of Sex Development Ja Kim (Guri City, Republic of Korea)
10:35	FC7.6	Whole-Exome Sequencing Reveals RAD51B Variant in Two Sisters with Primary Ovarian Failure Monica Franca (Sao Paulo, Brazil)
09:15-10:45		RFC & FC 8 - Growth: Clinical Chair(s):Pierre Bougnères (Paris, France) & Susan O’Connell (Cork, Ireland) Salle Maillot
	RFC8.1	Somavaratan (VRS-317) Treatment of Children with Growth Hormone Deficiency (GHD): Results at 2 Years (NCT02068521) Bradley Miller (USA)
	RFC8.2	Pharmacokinetic Modelling predicts native hGH levels following administration of a sustained-release prodrug, TransCon hGH, to children with GHD. Kennett Sprogøe (Palo Alto, USA)
	RFC8.3	Batch-to-Batch Consistency of a Highly O-Glycosylated Long-Acting Human Growth Hormone (MOD-4023) Oren Hershkovitz (Nes Ziona, Israel)
	RFC8.4	A hybrid Fc-fused human growth hormone, GX-H9, shows a potential for weekly and semi-monthly administration in clinical studies EunJig Lee (Seoul, Republic of Korea)
	RFC8.5	Optimal Sampling of IGF-1 During Weekly Administration of a Long Acting Human Growth Hormone (MOD 4023) Gili Hart (Nes Ziona, Israel)
	RFC8.6	A Six-Month Safety and Efficacy Study of TransCon hGH Compared to Daily hGH in Pre-Pubertal Children with Growth Hormone Deficiency (GHD) Pierre Chatelain (Lyon, France)
	RFC8.7	Safety and Tolerability of Once-Weekly Administration of CTP-Modified Human Growth Hormone (MOD-4023): 24-month Complete Dataset Results of a Phase 2 Study in Children with Growth Hormone Deficiency Gili Hart (Nes Ziona, Israel)
	RFC8.8	Efficacy of Once-Weekly Administration of CTP-Modified Human Growth Hormone (MOD-4023): 24-Month Complete Database Results of a Phase 2 Study in Children with Growth Hormone Deficiency Gili Hart (Nes Ziona, Israel)
09:45	FC8.1	Transcriptomics and Machine Learning Methods Accurately Predict Diagnosis and Severity of Childhood Growth Hormone Deficiency Philip Murray (Manchester, UK)
09:55	FC8.2	Whole exome sequencing can identify defects not detected by candidate gene sequencing in patients with short stature and features of growth hormone insensitivity (GHI) Lucy Shapiro (London, UK)
10:05	FC8.3	PAPP-A2 Gene Mutation Effects on Glucose Metabolism and Bone Mineral Density and Response to Therapy with Recombinant Human IGF-I Catalina Salcedo (Cincinnati, USA)
10:15	FC8.4	Genetic Insights from Children with Idiopathic Short Stature in the EPIGROW Study Reena Perchard (University of Manchester, Manchester, UK)
10:25	FC8.5	Longitudinal study on body composition, insulin sensitivity and β-cell function in SGA adults from stop of long-term GH treatment until 5 years after stop Manouk Steen (Rotterdam, The Netherlands)
10:35	FC8.6	Birth characteristics explain one third of expected deaths in rhGH-treated patients diagnosed with IGHD, ISS & SGA. Kerstin Albertsson-Wikland (Gothenburg, Sweden)
09:15-10:45		RFC & FC 9 - Pathophysiology of Disorders of Insulin Secretion Chair(s):Marc Nicolino (Lyon, Frace) & Carine de Beaufort (Luxenbourg, Luxenbourg) 252 AB L2
	RFC9.1	Neonatal diabetes due to NKX2.2 mutation – Genotype, clinical phenotype and therapeutic challenges in a very low birth weight diabetic neonate Adi Auerbach (Jerusalem, Israel)
	RFC9.2	Missense mutation of GLIS3 gene resulting inneonatal diabetes and congenital hypothyroidism Nadia Alghazir (Tripoli, Libya)
	RFC9.3	Molecular analysis of a large cohort of MODY patients by Next Generation Sequencing. Rosangela Artuso (Florence, Italy)
	RFC9.4	Prevalence of monogenic diabetes in the Lithuanian paediatric and young adult population Valerie Schwitzgebel (Geneva, Switzerland)
	RFC9.5	Non-mody monogenic diabetes: A very heterogenous and problematic group of diabetes Zeynep Siklar (Ankara, Turkey)
	RFC9.6	Emerging pitfalls of etiological diagnosis of diabetes in children and adolescents? Analysis of a French cohort of 310 recent-onset cases Elise Bismuth (Saint Pierre, Reunion)
	RFC9.7	Chronotype and Type 2 Diabetes Risk in Preadolescents Magdalena Dumin (Chicago, USA)
	RFC9.8	Micro RNAs and Diabetic Nephropathy Shereen Abdelghaffar (Cairo, Egypt)
09:45	FC9.1	Next generation sequencing for the diagnosis of monogenic diabetes in Switzerland Philippe Klee (Geneva, Switzerland)
09:55	FC9.2	NBAS mutations, a new monogenic cause of DISOPHAL, a new syndrome with Type 1 diabetes (T1D). Dr. Anya Rothenbuhler (Paris, France)
10:05	FC9.3	Gastrointestinal dysmotility and pancreatic exocrine insufficiency as newly recognised possible features in two siblings with Donohue syndrome Eirini Kostopoulou (London, UK)
10:15	FC9.4	The Protective Effects of Adenovirus-mediated IL-10 Gene and Anti-CD20 Monoclonal Antibody on the Pancreatic β Cells of NOD Mice in the Early Stage of Natural T1D Onset Tang Li (Shandong, China)
10:25	FC9.5	Evaluation of a novel method to detect residual ß-cell function by dried blood spots in children and adolescents with a recent diagnosis of type 1 diabetes Ruben Willemsen (Cambridge, UK)
10:35	FC9.6	Circulating angiopoietin-2 levels in young patients with type 1 diabetes mellitus: A link between inflammation, micro-vascular complications and subclinical atherosclerosis Nancy Elbarbary (Cairo, Egypt)
10:45-11:15		Refreshment break, posters and exhibition Exhibition area
11:15-11:30		ESPE Awards Chair(s):Gary butler (London, UK) & Jan Lebl (Prague, Czech Republic) Outstanding Clinician Award, International Outstanding Clinician Award, Hormone Research in Paediatrics prizes Grand Amphithéâtre L2
11:30-12:00		Plenary 5 Chair(s):Mehul Dattani (London, UK) & Annette Grüters-Kieslich (Berlin, Germany) Grand Amphithéâtre L2
11:30	PL5	Genetics of common and uncommon obesity Philippe Froguel (London, UK)
12:15-13:45		RFC & FC 10 - Perinatal Endocrinology Chair(s):Veronica Mericq (Santiago, Chile) & Regis Coutant (Angers, France) Amphithéâtre Bleu L2
	RFC10.1	Paternal loss-of-function mutations of GNAS and growth retardation in a mice model: a specific placental transcriptomic signature? Lea Tran (Caen, France)
	RFC10.2	Dysregulation of placental mirna in maternal obesity is associated with pre-and post-natal growth Judit Bassols (Salt, Spain)
	RFC10.3	Vitamin D depletion in pregnancy decreases survival time, oxygen saturation, lung weight and body weight in preterm rat offspring. Sine Lykkedegn (Odense, Denmark)
	RFC10.4	Pharmacokinetics of Intravenous Glucagon in Children with Hyperinsulinaemic Hypoglycaemia Pratik Shah (London, UK)
	RFC10.5	Phenotype, Genotype and Short term Outcome in Congenital Hyperinsulinism (CHI) Mudita Dhingra (Mumbai, India)
	RFC10.6	Increased Islet Cell Neogenesis and Endocrine Cell Differentiation in Congenital Hyperinsulinism in Infancy Elise Hardwick (Manchester, UK)
	RFC10.7	Expression of Insulin Receptor Isoforms and Type 1 insulin-like growth factor receptor in the placenta as a function of fetal weight. Dov Tiosano (Haifa, Israel)
	RFC10.8	Gestational diabetes is associated with changes in placental microbiota and microbiome Judit Bassols (Salt, Spain)
12:45	FC10.1	CYP11B1 deficiency in very preterms: evidence for an adrenal cortex zone-specific and developmental-dependent maturation Simon Travers (Le Kremlin-Bicêtre, France)
12:55	FC10.2	Liver UPR and metabolic consequences in an animal model of intrauterine growth retardation (IUGR) Annalisa Deodati (Rome, Italy)
13:05	FC10.3	Pharmacokinetics of Long Acting Somatostatin Analogue (Lanreotide) therapy in Hyperinsulinaemic Hypoglycaemia (HH) and understanding its molecular action via somatostatin receptors by Immunohistochemistry Pratik Shah (London, UK)
13:15	FC10.4	In utero and postnatal consequences of psychological maternal stress have different effects on longevity: studies in World War 1 orphans. Nicolas Todd (Bicêtre, France)
13:25	FC10.5	Effects of developmental bisphenol A exposure on spermatozoal microRNA expression Benjamin Fisher (Cambridge, UK)
13:35	FC10.6	Developmental programming of somatic growth, behavior and the endocannabinoid system (ECS) by variation of early postnatal nutrition in a cross-fostering mouse model Felix Schreiner (Bonn, Germany)
12:15-13:45		RFC & FC 11 - Thyroid Chair(s):Paul Von Trotsenberg (Amsterdam, The Netherlands) & José Moreno (Madrid, Spain) Amphithéâtre Bordeaux L3
	RFC11.1	Central hypothyroidism and biallelic defect near the D/ERY motif of the TRHR gene Marta García (Madrid, Spain)
	RFC11.2	The incidence and genetic analysis of Congenital Hypothyroidism in Guangxi, China and the predictors for differentiating permanent and transient congenital hypothyroidism Shaoke Chen (Nanning, China)
	RFC11.3	Germline and somatic DICER1 mutations in familial Papillary Thyroid Carcinoma and Multinodular Goiter. César Lumbreras (Madrid, Spain)
	RFC11.4	Thyroid function in monozygotic twins with intra-twin birth-weight-differences Sandra Schulte (Bonn, Germany)
	RFC11.5	Novel homozygous mutation in the sodium/iodide symporter (NIS) gene highlight by next generation sequencing (NGS) in a patient with congenital hypothyroidism Isabelle Petit (Toulouse, France)
	RFC11.6	Falsely TSH and free thyroid hormone measurements in paediatric patients treated with high dose of biotin Moran Gal (Ramat Gan, Israel)
	RFC11.7	Secondary Thyroid cancer among childhood cancer survivors. A single institution experience. Monica Muraca (Genova)
12:45	FC11.1	Mutations in TBL1X as a novel cause of familial central hypothyroidism Charlotte Heinen (Amsterdam, The Netherlands)
12:55	FC11.2	Overexpression of DYRK1A, Located in the Down Syndrome Critical Region, Leads to Primary Hypothyroidism in Down Syndrome through Interaction with FOXE1 Dulanjalee Kariyawasam (Paris, France)
13:05	FC11.3	Genetic heterogeneity revealed by WES in a cohort of patients with Brain-Lung-Thyroid syndrome Anathanasia Stoupa (Paris, France)
13:15	FC11.4	Decreased proportions of CD4+IL17+/CD4+CD25+CD127- and CD4+IL17+/CD4+CD25+CD127-FoxP3+ T cells in children with autoimmune thyroid diseases. Artur Bossowski (Bialystok, Poland)
13:25	FC11.5	Paediatric reference values of thyrotropin (TSH) should be personalized according to child characteristics Joseph Meyerovitch (Petah Tikva, Israel)
13:35	FC11.6	Too many TFTs? A change in neonatal thyroid function testing in a peripheral hospital in Ireland. Aedin Collins (Dogheda, Ireland)
12:15-13:45		RFC & FC 12 - Neuroendocrinology Chair(s):Najiba Lahlou (Paris, France) & Lourdes Ibáñez (Barcelona, Spain) 252 AB L2
	RFC12.1	Molecular genetic diagnosis of idiopathic hypogonadotropic hypogonadism by using targeted next-generation sequencing Kohei Aoyama (Nagoya, Japan)
	RFC12.2	A novel mutation of KISS1R causing a normosmic isolated hypogonadotropic hypogonadism Keisuke Yoshii (Paris, France)
	RFC12.3	Next Generation Sequencing and precocious puberty: a new diagnostic challenge to identify the molecular basis of complex diseases Andrea Barbera (Florence, Italy)
	RFC12.4	Molecular screening of MKRN3, DLK1 and KCNK9 genes in central precocious puberty Anna Grandone (Naples, Italy)
	RFC12.5	A novel MKRN3 nonsense mutation causing familial central precocious puberty Athanasios Christoforidis (Thessaloniki, Greece)
	RFC12.6	Serum antimüllerian hormone and inhibin B as potential markers for progressive central precocious puberty in girls Ting Chen (Suzhou, China)
	RFC12.7	Prevalence of organic lesions in males with central precocious puberty Stefania Pedicelli (Rome, Italy)
	RFC12.8	Circulating MKRN3 levels decline during puberty in healthy boys Alexander Busch (Copenhagen, Denmark)
12:45	FC12.1	Rabconnectin3-α is indispensable for the Activation and Maturation of the GnRH Neuronal Network Brooke Tata (Paris, France)
12:55	FC12.2	LGR4 and EAP1 mutations are implicated in the phenotype of self-limited delayed puberty. Alessandra Mancini (London, United Kingdom)
13:05	FC12.3	Inactivating Mutations in CCDC141 Causing Idiopathic Hypogonadotrophic Hypogonadism/Kallmann Syndrome Ihsan Turan (Adana, Turkey)
13:15	FC12.4	Idiopathic Hypogonadotrophic Hypogonadism Caused by Inactivating Mutations in SRA1 Leman Kotan (Adana, Turkey)
13:25	FC12.5	Abnormal corticospinal tract decussation in Kallmann syndrome due to ANOS1 (KAL1) mutations: an explanation of the mirror movements frequently observed in these patients Laura González-Briceño (Paris, France)
13:35	FC12.6	Pubertal onset in boys is influenced by BMI and genetic variation of FSHB and FSHR: A study in two population-based cohorts of different genetic ancestry Alexander Busch (Copenhagen, Denmark)
12:15-13:45		RFC & FC 13 - Management of Obesity Chair(s):Bessie Spiliotis (Athens, Greece) & Antje Korner (Leipzig, Germany) Salle Maillot - L2
	RFC13.1	Inhibition of teneurin-2 (TENM2) leads to upregulation of UCP1 in human white adipocytes Daniel Tews (Ulm, Germany)
	RFC13.2	The use of proteomics in the assessment of health status of offspring born after intracytoplasmic sperm injection (ICSI) Ioanna Kosteria (Athens, Greece)
	RFC13.3	Effects of eating rate on satiety hormones, meal enjoyment and memory for recent eating: An fMRI study Katherine Hawton (Bristol, UK)
	RFC13.4	Which amount of BMI-SDS reduction is necessary to improve cardiovascular risk factors in overweight and obese children? Thomas Reinehr (University of Witten/Herdecke, Datteln, Germany)
	RFC13.5	Protective potential of Metformin on membrane linked functions in diabetic aging female rats. Pardeep Kumar (New Delhi, India)
	RFC13.6	Outcome of Sleeve gastrectomy in the Lebanese adolescent population Mohamad Elfawal (Beirut, Lebanon)
	RFC13.7	Early-onset obesity and hyperphagia associated with defects in the GNAS gene Marta García (Madrid, Spain)
	RFC13.8	Measuring subcutaneous adipose tissue using ultrasound in children Adela Chirita-Emandi (Timisoara, Romania)
12:45	FC13.1	Quantitative proteomic of rat livers shows a major reprogramming of mitochondrial enzymes in food-restriction and increased stress hallmarks in ad libitum feeding Galia Gat-Yablonski (Petach-Tikva, Israel)
12:55	FC13.2	Measurement of immunofunctional leptin to detect patients with functional leptin deficiency Professor Martin Wabitsch (University of Ulm, Germany)
13:05	FC13.3	Hypothalamic gliosis in obese children and adolescents Leticia Sewaybricker (Sao Paulo, Brazil)
13:15	FC13.4	Efficacy and safety of duodenal-jejunal bypass liner in morbidly obese adolescents-1 year experience Primoz Kotnik (Ljubljana, Slovenia)
13:25	FC13.5	Effects of AZP-531, a first-in-class unacylated ghrelin analog, on food-related behaviour in Prader-Willi patients: a multi-center, randomized, placebo-controlled study Maithé Tauber (Toulouse, France)
13:35	FC13.6	Treatment for early onset and extreme obesity in two POMC deficient patients: Successful weight loss with the melanocortin-4 receptor agonist setmelanotide Peter Kühnen (Berlin, Germany)
12:15-13:45		RFC & FC 14 - Growth : Mechanisms Chair(s):Frederic Brioude (Paris, France) & Weiland Kiess (Leipzig, Germany) 342 AB L3
	RFC14.1	Important contribution of GH, GHRHR and GHSR mutations in isolated growth hormone deficiency with a normal location of the posterior pituitary –Functional characterization of new variants Enzo Cohen (Paris, France)
	RFC14.3	Whole Exome Sequencing Identifies a GH1 Gene Mutation Causing Familial Isolated Growth Hormone Deficiency with Normal Peak Growth Hormone Concentrations Catalina Salcedo (Cincinnati, USA)
	RFC14.2	Contribution of GHR and IGFALS mutations to growth hormone resistance – Identification of new variants and impact on the inheritance pattern Marie Legendre (Paris, France)
	RFC14.4	Genetic diagnosis of congenital growth hormone deficiency by massive parallel sequencing using a target gene panel Marilena Nakaguma (Sao Paulo, Brazil)
	RFC14.5	Gene Expression Profiling of Children with GH Deficiency (GHD) Prior to Treatment with Recombinant Human Growth Hormone (r-hGH) is Associated with Growth Response Over Five Years of Therapy Adam Stevens (Manchester, United Kingdom)
	RFC14.6	Effect of small size at birth, adult body size and growth hormone treatment on telomere length Carolina Smeets (Rotterdam, The Netherlands)
	RFC14.7	GH influences plasma fasting adropin concentration in patients with Turner syndrome Beata Wikiera (Wroclaw, Poland)
	RFC14.8	ACAN mutations in short children born SGA; growth response during GH treatment with additional GnRHa, and a proposed clinical scoring system. Manouk Steen (Rotterdam, The Netherlands)
12:45	FC14.1	Clinical characterization of children with autosomal dominant short stature due to aggrecan mutations broadens the phenotypic spectrum Alexandra Gkourogianni (Athens, Greece)
12:55	FC14.2	CG methylation at the IGF1 P2 promoter is a major epigenetic determinant of postnatal, not foetal growth. Myriam Ouni (Bicêtre, France)
13:05	FC14.3	CG at the methylation IGF1 locus is an epigenetic predictor of GH sensitivity. Myriam Ouni (Bicêtre, France)
13:15	FC14.4	Preferential paternal transmission of the T allele for the rs1802710 polymorphism in Dlk1 gene as a pre- and postnatal growth regulator Anna Prats-Puig (Girona, Spain)
13:25	FC14.5	Preferential transmission of the paternal C allele of the rs9373409 polymorphism in PLAGL1 gene as a regulator of fetal growth and maternal metabolism Anna Prats-Puig (Girona, Spain)
13:35	FC14.6	In vitro and in vivo evidence for a growth inhibitory role of the transcription factor ZBTB38 throughout pre- and post-natal life Sam Parsons (Manchester, UK)
12:15-13:45		RFC & FC 15 : Late Breaking Chair(s):Sandro Loche (Cagliari, Italy) & Lars Savendahl (Stockholm, Sweden) Grand Amphithéâtre L2
	RFC15.1	A novel homozygous mutation in the domain AF-2 of alpha estrogen receptor gene (ESR1), generating a bio-inactive ERα mutant, resulting in estrogen resistance with complex metabolic phenotype. Eva Feigerlova (Nancy, France)
	RFC15.2	NR0B1 Frameshift Mutation in a Boy with Precocious Puberty and Normal Adrenal Function Hirohito Shima (Tokyo, Japan)
	RFC15.4	The Effect of Sfrp5, Wnt5a, Adiponectin, and Chemerin on Blood Pressure Regulation in Obese Children Yan Xiao (Xi'an, China)
	RFC15.5	Effect of melatonin on proliferation and differentiation of human dental pulp cells Hongwen He (Guangzhou, China)
	RFC15.6	Safety of GH in Paediatrics: The GeNeSIS Prospective Observational Study Experience Between 1999 and 2015 Christopher Child (Surrey, UK)
	RFC15.7	Long-term safety and effectiveness of daily and weekly growth hormone treatment in paediatric GHD patients (4-years’ results) Sochung Chung (Seoul, Republic of Korea)
	RFC15.8	Replacement Of Male Mini-Puberty Dimitrios Papadimitriou (Athens, Greece)
12:45	FC15.1	NR5A1 is a novel disease gene for 46,XX testicular and ovotesticular disorders of development Dorien Baetens (Ghent, Belgium)
12:55	FC15.2	Mutations in SGPL1, the gene encoding sphingosine-1-phosphate lyase, cause a novel form of primary adrenal insufficiency with steroid resistant nephrotic syndrome Rathi Prasad (London, UK)
13:05	FC15.3	Contribution of next generation sequencing approach for management of congenital hypothyroidism with eutopic gland Isabelle Petit (Toulouse, France)
13:15	FC15.4	Vitamin D-dependent rickets type 1 caused by mutations in CYP27B1 affecting protein interactions with adrenodoxin Amit Pandey (Bern, Switzerland)
13:25	FC15.5	Effect of Conjugated Linoleic Acid and Metformin on Insulin Sensitivity, measured by Euglycemic-Hyperinsulinemic Clamp Technique, in Children with obesity: A Randomized, Double-Blinded, Placebo-Controlled Trial. Nayley Garibay (Mexico City, Mexico)
13:35	FC15.6	Type 1 diabetes associated serum Insulin-like growth factor I (IGF-I) reference values in children and adolescents Daniel Öberg (Västervik, Sweden)
13:45-15:15		Lunch, posters and exhibition Exhibition area
13:45-15:15		ESPE Activities Update Chair(s):Jan Lebl (Prague, Czech Republic), Rasa Verkauskiene (Kaunas, Lithuania), Faisal Ahmed (Glasgow, UK) & Martine Cools (Ghent, Belgium) 252 AB
		The Summer School Training Opportunity – a view from the faculty Johnny Deladoey (Montreal, Canada)
		The Summer School Training Opportunity – the trainees’ perspective Júlia Galhardo (Lisbon, Portugal)
		Winter School update John Gregory (Cardiff, UK)
		Winter School from a fellow’s perspective Lusine Kalantaryan (Yerevan, Armenia)
		Success of paediatric endocrinology training in North Africa
		ESPE-ASPED School update
		Caucasus & Central Asia school oppurtunities Rasa Verkauskiene (Kaunas, Lithuania)
		Fellow's feedback from the 2nd ESPE Caucasus & Central Asia School in Tashkent Olessya Mikhailyuk ()
		Diabetes, Obesity & Metabolism (DOM) school update Moshe Philip (Petah Tikva, Israel)
		Clinical fellowship programme: past and future Rasa Verkauskiene (Kaunas, Lithuania)
		ESPE Clinical Fellowship: from inspiration to new horizons Evgenia Globa ()
		Maintaining Paedeatric Endocrine Training Centres for Africa (PETCA), the best ESPE educational activity Ieuan Hughes (Cambridge, UK)
		Review of the ETC over the last 6 years Jan Lebl (Prague, Czech Republic)
		ESPE Science Committee Activity updates: Introduction Faisal Ahmed (Glasgow, United Kingdom)
		ESPE research unit Irène Netchine (Paris, France)
		Science workshop
		Research fellowship Katharina Main (Copenhagen, Denmark)
		Early career scientific development award Faisal Ahmed (Glasgow, United Kingdom)
		Mid-career scientific development award Outi Mäkitie (Helsinki, Finland)
		Expert panel Martine Cools (Ghent, Belgium)
14:00-15:00		Industry Sponsored Satellite Symposia Salle Maillot L2
15:15-16:15		Meet the Expert 6 (repeated) 252 AB L2
15:15	MTE6.2	Prolactinomas in adolescence Philip Chanson (Paris, France)
15:15-16:15		Meet the Expert 7 (repeated) Salle Maillot L2
15:15	MTE7.2	Neonatal hypocalcaemia Serap Turan (Istanbul, Turkey)
15:15-16:15		Meet the Expert 8 (repeated) 342 AB L3
15:15	MTE8.2	Steroid measurements in paediatric endcrinology Yves Morel (Lyon, France)
15:15-16:45		Symposium 8: Stem cells in endocrine organs Chair(s):Ivo Arnhold (São Paolo, Brazil) & Martin Wabitsch (Ulm, Germany) Amphithéâtre Bleu L2
15:15	S8.1	Pituitary stem cells Cynthia Andoniadou (London, UK)
15:45	S8.2	Pluripotent stem cells in endocrinology Rudolph Leibel (New York, USA)
16:15	S8.3	Hubs in the pancreas David Hodson (University of Oxford, Oxford, UK)
15:15-16:45		Symposium 9: Recent advances in congenital adrenal hyperplasia Chair(s):Evangelia Charmandari (Athens, Greece) & Stefan Wudy (Giessen, Germany) Grand Amphithéâtre L2
15:15	S9.1	Long-term health in congenital adrenal hyperplasia: lessons from a national study Anna Nordenström (Karolinska University Hospital, Stockholm, Sweden)
15:45	S9.2	New approaches to glucocorticoid replacement Richard Ross (Sheffield, UK)
16:15	S9.3	New approaches to limit glucocorticoid exposure Richard Auchus (Michigan, USA)
15:15-16:45		Symposium 10: Endocrine management of preterms Chair(s):Margaret Zacharin (Melbourne, Australia) & Gabriel Á Martos-Moreno (Madrid, Spain) Amphithéâtre Bordeaux L3
15:15	S10.1	Glucose metabolism and management in premature babies Kathryn Beardsall (Cambridge, UK)
15:45	S10.2	The gonadotropic axis in premature babies Leo Dunkel (London, UK)
16:15	S10.3	The mineralcorticoid system and its implications for neonatal adaptation in premature babies Laetitia Martinerie (Paris, France)
16:45-		Exhibition closes
16:45-17:15		ESPE Awards Chair(s):Peter Clayton (Manchester, UK) & Jean-Claude Carel (Paris, France) ESPE International Award, ESPE president poster award Grand Amphithéâtre L2
17:15-17:45		Plenary 6 Chair(s):Moshe Phillip (Petah Tikva, Israel) & Tadej Battelino (Ljubljana, Slovenia) Grand Amphithéâtre L2
17:15	PL6	Cell therapy in Type 1 diabetes Bart Roep (Leiden, The Netherlands)
17:45-18:00		Closing Ceremony Jean-Claude Carel, Peter Clayton & Mehul Dattani Grand Amphithéâtre L2

ESPE2016

10 September 2016

11 September 2016

12 September 2016